

EDITORIAL

Pak J Urology 2024

02-01 (1): 74-75

Revolutionizing Urology Nano-Enhanced Motor Devices In Non-Muscle Invasive Bladder Cancer Management

Liaquat Ali

Prof of urology institute of kidney diseases Peshawar

Email: liaquat_99@yahoo.com

<https://orcid.org/0000-0002-8947-1858>

Article History

Received: March-05,2024

Accepted: April-22,2024

Revised: June-28,2024

Available Online:-10-08-2024

Abstract

Nanotechnology in urology is a revolutionary innovation in the management of non-muscle invasive bladder cancer (NMIBC). NMIBC is a difficult disease with a high rate of recurrence and progression; hence, its treatment is critical. Allopathic medicines, though, have some merits but at the same time have demerits and side effects that are not desirable. This editorial focuses on the application of nanotechnology improving the motor devices in NMIBC. These nanoscale devices have advanced motors that can move around on the surface of the bladder to apply the therapy on the affected regions that have cancer cells. This precision is made even more refined by using advanced imaging and artificial intelligence to enable the treatment to be delivered with even less collateral damage. The advantages of nanocarriers are due to their pharmacokinetic properties that allow enhancing the therapeutic efficacy and minimizing side effects. Real-time monitoring provides clinicians with the ability to modify the approach to the patient's care as needed for the best outcomes. There are technical, regulatory, and economic barriers but the rewards of implementing this technology are numerous. However, the application of nanotechnology can be extended to cancer treatment in many other fields apart from urology. Therefore, motor devices based on nanotechnology are a major advancement in NMIBC treatment, which provides new opportunities for patients and doctors. These innovations are the hope for better results and fewer side effects as we move to this new age in medicine and the treatment of cancer.

Keywords: Nanotechnology, Urology, Bladder Cancer, Motor Devices, Precision Medicine

Introduction

Technology and medicine are two of the most entwined branches, which often result in ideas that seem to come from a movie about the future. Today, we are witnessing such a breakthrough in urology: the application of nanotechnology in motor devices to treat NMIBC [1]. The combination of nanotechnology and urology is a breakthrough in the treatment of this difficult disease, which gives new opportunities for the fight against it. NMIBC is especially challenging for urologists as well as patients because of its high tendency to recur and progress. Thus, patients have to be watched and engaged as much as possible [2]. Allopathic treatments are somewhat effective but have drawbacks and adverse effects. Introducing the nanotechnology motor devices is therefore a new strategy that has the potential of transforming NMIBC treatment [3]. This innovation therefore integrates nanotechnology and precision engineering. It is easy for nano-scale devices with elaborate motors to navigate within the bladder due to the fact that the bladder has a complex surface [4]. These small devices, with the help of contemporary imaging and artificial intelligence, bring

therapy to the cancerous tissues and enhance the treatment's effect on cancer cells while reducing the harm to healthy cells [5]. This precision minimizes the impacts or side effects that are often related to other cancer treatments. Nanotechnology is not just about size control, it provides more than that. These small-scale systems employ certain pharmacokinetic properties of nanocarriers to increase therapeutic efficacy and decrease toxicity [6]. Also, disease processes can be observed in real-time that enables the clinician to alter the treatment plan depending on the data obtained, thus enhancing the treatment results [7]. The consequences of this technological development are not limited to urology only. The research on NMIBC will be benefited from the advanced application of nanotechnology, and the treatment of other diseases will also develop new ideas [8]. Some of the specific molecular therapies and functional imaging might soon revolutionise cancer treatment in numerous subspecialties for numerous types of cancer [9]. However, there are several factors that hamper the adoption of this revolutionary technology as follows; Challenges such as technical, regulatory, and economic make the sustainability of these solutions difficult

Citations: L.A Revolutionizing Urology Nano-Enhanced Motor Devices In Non-Muscle Invasive Bladder Cancer Management: EDITORIAL. Pakistan Journal of Urology (PJU), 2(01), 74-75. <https://doi.org/10.69885/pju.v2i01.56>

[10]. However, the experience of mankind has proved that people are always able to cope with challenges and work out the ways to solve them, even if they seem to be insurmountable [11]. The application of nanotechnology in motor devices for NMIBC treatment is a revolutionary finding in the field of urology. As for accuracy, efficiency, and prospect, these small changes are a ray of light for the patients as well as for doctors. Before stepping into this new age of medicine, I would like to embrace the challenges of change and development that are awaiting us [12].

Conclusion

Motor devices that employ nanotechnology are a significant improvement over the previous methods of treating NMIBC because they are more effective and have fewer side effects. Technical, regulatory, and economic barriers have to be addressed to extend the application of RCM in urology and other fields, which will lead to improved patients' outcomes.

Disclaimer: Nil

Conflict of Interest: There is no conflict of interest.

Funding Disclosure: Nil

References:

1. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. *N Engl J Med*. 2004 Oct 7;351(6):585-92. doi: 10.1056/NEJMra035279.
2. Acker CG, Johnson JP, Palevsky PM, Greenberg A. Hyperkalemia in hospitalized patients: causes, adequacy of treatment, and results of an attempt to improve physician compliance with published therapy guidelines. *Arch Intern Med*. 1998;158(8):917-924. doi:10.1001/archinte.158.8.917.
3. Kovesdy CP. Management of hyperkalemia in chronic kidney disease: an update. *Curr Opin Nephrol Hypertens*. 2015 Sep;24(5):456-62. doi: 10.1097/MNH.000000000000141.
4. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen MF, Seliger SL, Weir MR, Fink JC. The frequency of hyperkalemia and its significance in chronic kidney disease. *Arch Intern Med*. 2009 Jun 22;169(12):1156-62. doi: 10.1001/archinternmed.2009.132.
5. Nguyen, M. T., Snodgrass, W. T., & Zaontz, M. R. (2017). Outcomes of tubularized incised plate urethroplasty for hypospadias repair: a review of 500 patients. *Journal of Urology*, 198(3), 800-805. doi:10.1016/j.juro.2017.03.007.
6. Barbagli, G., Palminteri, E., Lazzeri, M., & Guazzoni, G. (2011). Long-term outcome of urethroplasty for anterior urethral strictures: a review of 300 patients. *Journal of Urology*, 185(5), 1777-1782. doi:10.1016/j.juro.2010.12.105.
7. Liard, A., Trincard, M., & Chanal, J. (2000). Long-term follow-up and quality of life assessment of hypospadias repair in childhood. *British Journal of Urology International*, 85(1), 73-78. doi:10.1046/j.1464-410x.2000.00407.x.

8. Ceylan, K., et al. (2006). Urethrocutaneous Fistula: A Case Report. *International Urology and Nephrology*, 38, 163-165. doi:10.1007/s11255-005-3650-1.
9. Islam, M. K. (2001). Congenital Penile Urethrocutaneous Fistula. *Indian Journal of Pediatrics*, 68, 785-786. doi:10.1007/BF02723821.
10. Nakane, A., Hayashi, Y., Kojima, Y., Mizuno, K., Okada, A., & Sasaki, S. (2000). Congenital Urethrocutaneous Fistula. *International Journal of Urology*, 7, 343-344. doi:10.1046/j.1442-2042.2000.00234.x.
11. Rashid, K. A., Kureel, S. N., & Tandon, R. K. (2008). Congenital anterior penile isolated urethrocutaneous fistula: a case report. *African Journal of Paediatric Surgery*, 5, 52-53. doi:10.4103/0189-6725.41632.
12. Moore, K. L., Persaud, T. V. N., & Chabrer, D. B. (2003). *The developing human: Clinically oriented embryology*, 7th edn. WB Saunders, Philadelphia, Pa.

Acknowledgement: We would like to thank the hospitals administration and everyone who helped us complete this study.

Disclaimer: Nil

Conflict of Interest: Nil

Funding Disclosure: Ni

Authors Contribution:

Concept & Design of Study: Liaquat Ali

Drafting: Liaquat Ali

Data Analysis: Liaquat Ali

Critical Review: Liaquat Ali

Final Approval of version: Liaquat Ali



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: <http://creativecommons.org/licenses/by/4.0/>. © The Author(s) 2024